# US 2026/0009003 A1 · Manufacturing of therapeutic satellite cells for treating muscular dystrophy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0009003 A1
- Document ID: US20260009003A1
- Status: Published application
- Kind: A1
- Application number: 18/993,492
- Filed: 2023-07-11
- Published: 2026-01-08
- Earliest claimed: 2022-07-11
- Assignees: Vita Therapeutics, Inc.
- Applicants: Vita Therapeutics, Inc.
- Inventors: Congshan SUN; Amir SABERI; Peter Andersen; Douglas FALK; Yongming REN; Sheela JACOB; Jeff HARDING; Amy WESA
- Web page: https://patentgrep.com/patent/US20260009003A1

## CPC

- C12N 5/0659: {Satellite cells}
- C12N 15/907: {in mammalian cells}
- A61K 35/34: Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes (vascular smooth muscle A61K35/44)
- A61K 35/545: Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61K 48/0058: {Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct}
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- C12N 5/10: Cells modified by introduction of foreign genetic material
- C12N 9/6472: {Cysteine endopeptidases (3.4.22)}
- C12N 15/85: for animal cells
- C12Y 304/22054: Calpain-3 (3.4.22.54), i.e. calpain p94
- C12N 2501/115: Basic fibroblast growth factor (bFGF, FGF-2)
- C12N 2501/119: Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
- C12N 2501/15: Transforming growth factor beta (TGF-β)
- C12N 2506/45: from artificially induced pluripotent stem cells
- C12N 2510/00: Genetically modified cells
- C12N 2533/52: Fibronectin; Laminin
- C12N 2830/008: cell type or tissue specific enhancer/promoter combination
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

The present disclosure provides compositions and methods for preparing autologous satellite cells that have restored a dysfunctional gene involved in muscular dystrophy of a patient. Such implanted satellite cells can promote repair and recovery of myofibrils and muscles in the patients, thereby treating muscular dystrophy in the patient.

## Claims

### Claim 1

A method for preparing a satellite cell from a stem cell comprising a mutation in an endogenous gene, comprising:
introducing to the stem cell a first and a second vectors, each comprising a first expression cassette encoding at least part of the wild-type gene, such that each of the first expression cassettes is integrated at a locus of the endogenous gene in the genome to enable coding of a wild-type version of the gene without the mutation;
differentiating the stem cell into a satellite cell; and
expanding the satellite cell into a population of satellite cells.

### Claim 2

A method for preparing a satellite cell from a stem cell comprising a mutation in an endogenous gene, comprising:
introducing to the stem cell a first and a second vectors, each comprising a first expression cassette comprising all coding sequences of the wild-type gene, such that each of the first expression cassettes is integrated at a locus in the genome different from the endogenous gene;
differentiating the stem cell into a satellite cell; and
expanding the satellite cell into a population of satellite cells.

### Claim 3 (depends on 2)

The method of claim 2, wherein the locus is selected from the group consisting of an intron of the AAVS1 gene, and human genome 195,338,589-195,818,588, 22,720,711-22,761,389, 145,090,941-145,219,513, 145,320,384-145,525,881, and 89,174,426-89,179,074 (GRCh38 coordinates).

### Claim 4 (depends on 3)

The method of claim 3, wherein the locus is in intron 1 of the AAVS1 gene.

### Claim 5 (depends on 2)

The method of claim 2, wherein the expression cassette further comprises a promoter capable to initiating expression of the coding sequences in a muscle cell.

### Claim 6 (depends on 5)

The method of claim 5, wherein the promoter is a muscle creatine kinase promoter (tMCK).

### Claim 7 (depends on 1)

The method of claim 1, wherein the mutation is a homozygous mutation.

### Claim 8 (depends on 1)

The method of claim 1, wherein the stem cell is an induced pluripotent stem cell (iPSC) derived from a peripheral blood mononuclear cell or fibroblast isolated from a patient having muscular dystrophy.

### Claim 9 (depends on 8)

The method of claim 8, wherein the muscular dystrophy is selected from the group consisting of limb-girdle muscular dystrophy, Becker muscular dystrophy, congenital muscular dystrophy, Duchenne muscular dystrophy, distal muscular dystrophy, Emery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy, myotonic muscular dystrophy, and oculopharyngeal muscular dystrophy.

### Claim 10 (depends on 1)

The method of claim 1, wherein the gene is selected from the group consisting of CAPN3, DNAJB6, TNPO3, HNRPDL, CAPN3, COL6A1, COL6A2, COL6A3, DYSF, SGCA, SGCB, SGCG, SGCD, TCAP, TRIM32, FKRP, TTN, POMT1, ANO5, FKTN, POMT2, POMGNT1, DAG1, PLEC1, TRAPPC11, GMPPB, ISPD, POGLUT1, COL6A1, COL6A2, COL6A3, LAMA2, POMGNT2, POPDC1, POPDC3, JAG2, PYROXD1, DMD, LAMA-2, DMD, DYSF, DMPK, CNBP, DUX4, PABPN1, EMD, LMNA,, SYNE1, SYNE2, FHL1, and TMEM43.

### Claim 11 (depends on 10)

The method of claim 10, wherein the gene is CAPN3.

### Claim 12 (depends on 11)

The method of claim 11, wherein the at least part of the wild-type CAPN3 gene does not include exon 1 or 2, and the locus is downstream of exon 2 of the endogenous CAPN3 gene.

### Claim 13 (depends on 12)

The method of claim 12, wherein the at least part of the wild-type CAPN3 gene comprises exons 3-24, and the locus is 3′ to the last nucleotide of exon 2 of the endogenous CAPN3 gene.

### Claim 14 (depends on 1)

The method of claim 1, wherein the first vector further comprises a second expression cassette encoding a first selection marker, and the second vector further comprises a third expression cassette encoding a second selection marker, wherein the first expression cassette and the second expression cassette on the first vector together are integrated into the genome, and the first expression cassette and the third expression cassette on the second vector together are integrated into the genome.

### Claim 15 (depends on 14)

The method of claim 14, wherein the second and third expression cassettes are excised from the genome following confirmation of the integration.

### Claim 16 (depends on 1)

The method of claim 1, wherein the first vector and second vector each further comprises a fourth expression cassette encoding a kill switch, which is not integrated to the loci.

### Claim 17 (depends on 1)

The method of claim 1, further comprising, prior to differentiation, culturing the stem cell in a vessel coated with an adhesion molecule.

### Claim 18 (depends on 17)

The method of claim 17, wherein the adhesion molecule is laminin-511 or a fragment thereof.

### Claim at position 19

19-22. (canceled)

### Claim 23 (depends on 1)

The method of claim 1, wherein the satellite cell is identified with an antibody specific to CD271.

### Claim 24

(canceled)

### Claim 25 (depends on 1)

The method of claim 1, further comprising administering the prepared satellite cell to a patient having the mutation.
